<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="4482">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01245751</url>
  </required_header>
  <id_info>
    <org_study_id>V211-029</org_study_id>
    <nct_id>NCT01245751</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability, and Immunogenicity of a Booster Dose of Zoster Vaccine, Live (V211-029)</brief_title>
  <official_title>Safety, Tolerability and Immunogenicity of a Booster Dose of ZOSTAVAX™ Administered ≥10 Years After a First Dose Compared With a First Dose of ZOSTAVAX™</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Colorado, Denver</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is being conducted to obtain safety and immunogenicity data after a booster dose
      of Zoster Vaccine, Live administered ≥10 years following an initial dose. This information
      will be compared to similar information obtained after Zoster Vaccine, Live administration
      to age-matched and younger participants who are receiving their first dose of Zoster
      Vaccine, Live. The study will determine: 1) whether a booster dose of Zoster Vaccine, Live
      in participants ≥70 years of age induces an antibody response that is noninferior to that of
      a first dose of Zoster Vaccine, Live in participants matched for age; 2) whether a booster
      dose of Zoster Vaccine, Live induces an acceptable rise in the level of varicella-zoster
      virus (VZV) antibodies.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      After completion of the 42-day postvaccination period, participants in Groups 3 and 4 will
      have 1 year postvaccination follow-up and participants in Groups 1 and 2 will have 3 years
      postvaccination follow-up.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2011</start_date>
  <completion_date type="Actual">May 2015</completion_date>
  <primary_completion_date type="Actual">July 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>Geometric Mean Titer (GMT) of the Antibody Responses to Varicella-Zoster Virus (VZV)</measure>
    <time_frame>Week 6 postvaccination</time_frame>
    <safety_issue>No</safety_issue>
    <description>VZV antibody titers were determined by glycoprotein enzyme-linked immunosorbent assay (gpELISA)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean Fold Rise (GMFR) From Day 1 to Week 6 Postvaccination in VZV Antibody Titers</measure>
    <time_frame>Day 1 and Week 6 postvaccination</time_frame>
    <safety_issue>No</safety_issue>
    <description>VZV antibody titers were determined by gpELISA. The GMFR measures the rise in VZV antibodies from Day 1 (Baseline) to Week 6 postvaccination.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Reporting One or More Adverse Experiences</measure>
    <time_frame>Up to 42 days postvaccination</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>An adverse experience (AE) is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study vaccine, whether or not considered related to the use of the product. Any worsening of a preexisting condition which is temporally associated with the use of the study vaccine is also an adverse experience.
A serious adverse experience is any AE that results in death, is life threatening, results in persistent disability/incapacity, results in or prolongs existing inpatient hospitalization, is a congenital anomaly/birth defect, is a cancer, is an overdose, or is another important medical event that may jeopardize the participant and may require medical or surgical intervention.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">600</enrollment>
  <condition>Herpes Zoster</condition>
  <arm_group>
    <arm_group_label>Group 1: Booster Dose Participants ≥70 years of age</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Herpes zoster history-negative participants ≥70 years of age who received Zoster Vaccine, Live approximately 10 years prior in the Shingles Prevention Study (NCT00007501)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2: First Dose Participants ≥70 years of age</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Herpes zoster history-negative participants ≥70 years of age who have never received Zoster Vaccine, Live and are matched to Group 1 participants by age</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3: First Dose Participants ≥60 and &lt;70 years of age</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Herpes zoster history-negative participants ≥60 and &lt;70 years of age who have never received Zoster Vaccine, Live</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 4: First Dose Participants ≥50 and &lt;60 years of age</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Herpes zoster history-negative participants ≥50 and &lt;60 years of age who have never received Zoster Vaccine, Live</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Zoster Vaccine, Live</intervention_name>
    <description>Single approximately 0.65-mL subcutaneous injection of Zoster Vaccine, Live on Day 1 of the study</description>
    <arm_group_label>Group 1: Booster Dose Participants ≥70 years of age</arm_group_label>
    <arm_group_label>Group 2: First Dose Participants ≥70 years of age</arm_group_label>
    <arm_group_label>Group 3: First Dose Participants ≥60 and &lt;70 years of age</arm_group_label>
    <arm_group_label>Group 4: First Dose Participants ≥50 and &lt;60 years of age</arm_group_label>
    <other_name>V211</other_name>
    <other_name>ZOSTAVAX™</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All Groups:

               -  Must not have a fever of ≥100.4° F on the day of vaccination

               -  Any underlying chronic illness must be in stable condition

               -  History of varicella or residence in a VZV-endemic area for ≥30 years

          -  Group 1:

               -  70 years of age or older

               -  Took part in the Shingles Prevention Study (SPS) (NCT00007501) and received a
                  single dose of Zoster Vaccine, Live ≥10 years prior to enrollment in this study

          -  Group 2:

               -  70 years of age or older

          -  Group 3:

               -  60 to 69 years of age

          -  Group 4:

               -  50 to 59 years of age

        Exclusion Criteria:

          -  All Groups:

               -  History of hypersensitivity reaction to any vaccine component or an
                  anaphylactic/anaphylactoid reaction to neomycin

               -  Prior history of herpes zoster

               -  Pregnant or breast-feeding, or expecting to conceive within the duration of the
                  study

               -  Has been treated with immunoglobulin or any blood products, other than
                  autologous (self-donated) blood transfusion, in the 5 months prior to
                  vaccination

               -  Received any other vaccine within 4 weeks prevaccination

               -  On immunosuppressive therapy

               -  Has known or suspected immune dysfunction

               -  Is taking any non-topical antiviral therapy with activity against herpesviruses,
                  including, but not limited to acyclovir, famciclovir, valacyclovir, and
                  ganciclovir.

          -  Groups 2, 3, and 4:

               -  Has previously received any varicella or zoster vaccine
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <results_reference>
    <citation>Levin MJ, Schmader KE, Pang L, Williams-Diaz A, Zerbe G, Canniff J, Johnson MJ, Caldas Y, Cho A, Lang N, Su SC, Parrino J, Popmihajlov Z, Weinberg A. Cellular and Humoral Responses to a Second Dose of Herpes Zoster Vaccine Administered 10 Years After the First Dose Among Older Adults. J Infect Dis. 2016 Jan 1;213(1):14-22. doi: 10.1093/infdis/jiv480. Epub 2015 Oct 9.</citation>
    <PMID>26452397</PMID>
  </results_reference>
  <verification_date>January 2016</verification_date>
  <lastchanged_date>January 25, 2016</lastchanged_date>
  <firstreceived_date>November 19, 2010</firstreceived_date>
  <firstreceived_results_date>April 10, 2013</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Shingles</keyword>
  <keyword>Vaccine</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Herpes Zoster</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Group 1: Booster Dose Participants ≥70 Years of Age</title>
          <description>Herpes zoster history-negative participants ≥70 years of age who received Zoster Vaccine, Live approximately 10 years prior in the Shingles Prevention Study (NCT00007501)</description>
        </group>
        <group group_id="P2">
          <title>Group 2: First Dose Participants ≥70 Years of Age</title>
          <description>Herpes zoster history-negative participants ≥70 years of age who have never received Zoster Vaccine, Live and are matched to Group 1 participants by age</description>
        </group>
        <group group_id="P3">
          <title>Group 3: First Dose Participants ≥60 and &lt;70 Years of Age</title>
          <description>Herpes zoster history-negative participants ≥60 and &lt;70 years of age who have never received Zoster Vaccine, Live</description>
        </group>
        <group group_id="P4">
          <title>Group 4: First Dose Participants ≥50 and &lt;60 Years of Age</title>
          <description>Herpes zoster history-negative participants ≥50 and &lt;60 years of age who have never received Zoster Vaccine, Live</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="201"/>
                <participants group_id="P2" count="199"/>
                <participants group_id="P3" count="100"/>
                <participants group_id="P4" count="100"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Completed 42-day Postvaccination Period</title>
              <participants_list>
                <participants group_id="P1" count="201"/>
                <participants group_id="P2" count="199"/>
                <participants group_id="P3" count="100"/>
                <participants group_id="P4" count="100"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0">Participants will complete the study after a 1-year postvaccination follow-up visit</participants>
                <participants group_id="P2" count="0">Participants will complete the study after a 1-year postvaccination follow-up visit</participants>
                <participants group_id="P3" count="0">Participants will complete the study after a 1-year postvaccination follow-up visit</participants>
                <participants group_id="P4" count="0">Participants will complete the study after a 1-year postvaccination follow-up visit</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="201"/>
                <participants group_id="P2" count="199"/>
                <participants group_id="P3" count="100"/>
                <participants group_id="P4" count="100"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Ongoing safety follow-up</title>
              <participants_list>
                <participants group_id="P1" count="201"/>
                <participants group_id="P2" count="199"/>
                <participants group_id="P3" count="100"/>
                <participants group_id="P4" count="100"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Group 1: Booster Dose Participants ≥70 Years of Age</title>
          <description>Herpes zoster history-negative participants ≥70 years of age who received Zoster Vaccine, Live approximately 10 years prior in the Shingles Prevention Study (NCT00007501)</description>
        </group>
        <group group_id="B2">
          <title>Group 2: First Dose Participants ≥70 Years of Age</title>
          <description>Herpes zoster history-negative participants ≥70 years of age who have never received Zoster Vaccine, Live and are matched to Group 1 participants by age</description>
        </group>
        <group group_id="B3">
          <title>Group 3: First Dose Participants ≥60 and &lt;70 Years of Age</title>
          <description>Herpes zoster history-negative participants ≥60 and &lt;70 years of age who have never received Zoster Vaccine, Live</description>
        </group>
        <group group_id="B4">
          <title>Group 4: First Dose Participants ≥50 and &lt;60 Years of Age</title>
          <description>Herpes zoster history-negative participants ≥50 and &lt;60 years of age who have never received Zoster Vaccine, Live</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="201"/>
                <measurement group_id="B2" value="199"/>
                <measurement group_id="B3" value="100"/>
                <measurement group_id="B4" value="100"/>
                <measurement group_id="B5" value="600"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="77.1" spread="4.5"/>
                <measurement group_id="B2" value="76.3" spread="5.1"/>
                <measurement group_id="B3" value="64.1" spread="3.1"/>
                <measurement group_id="B4" value="55.5" spread="2.8"/>
                <measurement group_id="B5" value="71.1" spread="9.4"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="107"/>
                <measurement group_id="B2" value="94"/>
                <measurement group_id="B3" value="65"/>
                <measurement group_id="B4" value="77"/>
                <measurement group_id="B5" value="343"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="94"/>
                <measurement group_id="B2" value="105"/>
                <measurement group_id="B3" value="35"/>
                <measurement group_id="B4" value="23"/>
                <measurement group_id="B5" value="257"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean Titer (GMT) of the Antibody Responses to Varicella-Zoster Virus (VZV)</title>
        <description>VZV antibody titers were determined by glycoprotein enzyme-linked immunosorbent assay (gpELISA)</description>
        <time_frame>Week 6 postvaccination</time_frame>
        <safety_issue>No</safety_issue>
        <population>Analysis included all vaccinated participants except those who had protocol deviations that interfered with the assessment of VZV antibody response, who developed varicella or herpes zoster rashes before a blood sample was taken, or who reported exposure to varicella or herpes zoster. The planned analysis included Group 1 versus Group 2 only.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: Booster Dose Participants ≥70 Years of Age</title>
            <description>Herpes zoster history-negative participants ≥70 years of age who received Zoster Vaccine, Live approximately 10 years prior in the Shingles Prevention Study (NCT00007501)</description>
          </group>
          <group group_id="O2">
            <title>Group 2: First Dose Participants ≥70 Years of Age</title>
            <description>Herpes zoster history-negative participants ≥70 years of age who have never received Zoster Vaccine, Live and are matched to Group 1 participants by age</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="198"/>
                  <measurement group_id="O2" value="194"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Geometric Mean Titer (GMT) of the Antibody Responses to Varicella-Zoster Virus (VZV)</title>
            <description>VZV antibody titers were determined by glycoprotein enzyme-linked immunosorbent assay (gpELISA)</description>
            <units>gpELISA Units/mL</units>
            <param>Geometric Mean</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="389.1" lower_limit="351.4" upper_limit="430.8"/>
                  <measurement group_id="O2" value="366.6" lower_limit="328.5" upper_limit="409.1"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority>Yes</non_inferiority>
            <non_inferiority_desc>The ratio of GMT values for Group 1/Group 2 is statistically non-inferior to the prespecified clinically relevant 1.5-fold if the lower bound of the 95% confidence interval is &gt;0.67</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The alpha threshold for statistical significance is 0.025 (1-sided)</p_value_desc>
            <method>Longitudinal regression model</method>
            <method_desc>The analyzed GMT ratio, 95% confidence interval, and P-value were based on a longitudinal regression model adjusting for age and vaccination group</method_desc>
            <param_type>GMT Ratio</param_type>
            <param_value>1.05</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.97</ci_lower_limit>
            <ci_upper_limit>1.15</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean Fold Rise (GMFR) From Day 1 to Week 6 Postvaccination in VZV Antibody Titers</title>
        <description>VZV antibody titers were determined by gpELISA. The GMFR measures the rise in VZV antibodies from Day 1 (Baseline) to Week 6 postvaccination.</description>
        <time_frame>Day 1 and Week 6 postvaccination</time_frame>
        <safety_issue>No</safety_issue>
        <population>Analysis included all vaccinated participants except those who had protocol deviations that interfered with the assessment of VZV antibody response, who developed varicella or herpes zoster rashes before a blood sample was taken, or who reported exposure to varicella or herpes zoster. The planned analysis included Group 1 only.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: Booster Dose Participants ≥70 Years of Age</title>
            <description>Herpes zoster history-negative participants ≥70 years of age who received Zoster Vaccine, Live approximately 10 years prior in the Shingles Prevention Study (NCT00007501)</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="198"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Geometric Mean Fold Rise (GMFR) From Day 1 to Week 6 Postvaccination in VZV Antibody Titers</title>
            <description>VZV antibody titers were determined by gpELISA. The GMFR measures the rise in VZV antibodies from Day 1 (Baseline) to Week 6 postvaccination.</description>
            <units>Fold Rise</units>
            <param>Geometric Mean</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="1.5" lower_limit="1.4" upper_limit="1.6"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>A booster dose induces a statistically acceptable VZV antibody response if the lower bound of the 95% confidence interval is &gt;1.0.</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The alpha threshold for statistical significance is 0.025 (1-sided)</p_value_desc>
            <method>Longitudinal regression model</method>
            <method_desc>The analyzed GMFR, 95% confidence interval, and P-value were based on a longitudinal regression model adjusting for age</method_desc>
            <param_type>Geometric mean fold rise</param_type>
            <param_value>1.54</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.44</ci_lower_limit>
            <ci_upper_limit>1.66</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Reporting One or More Adverse Experiences</title>
        <description>An adverse experience (AE) is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study vaccine, whether or not considered related to the use of the product. Any worsening of a preexisting condition which is temporally associated with the use of the study vaccine is also an adverse experience.
A serious adverse experience is any AE that results in death, is life threatening, results in persistent disability/incapacity, results in or prolongs existing inpatient hospitalization, is a congenital anomaly/birth defect, is a cancer, is an overdose, or is another important medical event that may jeopardize the participant and may require medical or surgical intervention.</description>
        <time_frame>Up to 42 days postvaccination</time_frame>
        <safety_issue>Yes</safety_issue>
        <population>Analysis included all vaccinated participants who had any safety follow-up</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: Booster Dose Participants ≥70 Years of Age</title>
            <description>Herpes zoster history-negative participants ≥70 years of age who received Zoster Vaccine, Live approximately 10 years prior in the Shingles Prevention Study (NCT00007501)</description>
          </group>
          <group group_id="O2">
            <title>Group 2: First Dose Participants ≥70 Years of Age</title>
            <description>Herpes zoster history-negative participants ≥70 years of age who have never received Zoster Vaccine, Live and are matched to Group 1 participants by age</description>
          </group>
          <group group_id="O3">
            <title>Group 3: First Dose Participants ≥60 and &lt;70 Years of Age</title>
            <description>Herpes zoster history-negative participants ≥60 and &lt;70 years of age who have never received Zoster Vaccine, Live</description>
          </group>
          <group group_id="O4">
            <title>Group 4: First Dose Participants ≥50 and &lt;60 Years of Age</title>
            <description>Herpes zoster history-negative participants ≥50 and &lt;60 years of age who have never received Zoster Vaccine, Live</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="201"/>
                  <measurement group_id="O2" value="199"/>
                  <measurement group_id="O3" value="100"/>
                  <measurement group_id="O4" value="100"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Participants Reporting One or More Adverse Experiences</title>
            <description>An adverse experience (AE) is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study vaccine, whether or not considered related to the use of the product. Any worsening of a preexisting condition which is temporally associated with the use of the study vaccine is also an adverse experience.
A serious adverse experience is any AE that results in death, is life threatening, results in persistent disability/incapacity, results in or prolongs existing inpatient hospitalization, is a congenital anomaly/birth defect, is a cancer, is an overdose, or is another important medical event that may jeopardize the participant and may require medical or surgical intervention.</description>
            <units>Participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="104"/>
                  <measurement group_id="O2" value="95"/>
                  <measurement group_id="O3" value="72"/>
                  <measurement group_id="O4" value="72"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 42 days postvaccination</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Group 1: Booster Dose Participants ≥70 Years of Age</title>
          <description>Herpes zoster history-negative participants ≥70 years of age who received Zoster Vaccine, Live approximately 10 years prior in the Shingles Prevention Study (NCT00007501)</description>
        </group>
        <group group_id="E2">
          <title>Group 2: First Dose Participants ≥70 Years of Age</title>
          <description>Herpes zoster history-negative participants ≥70 years of age who have never received Zoster Vaccine, Live and are matched to Group 1 participants by age</description>
        </group>
        <group group_id="E3">
          <title>Group 3: First Dose Participants ≥60 and &lt;70 Years of Age</title>
          <description>Herpes zoster history-negative participants ≥60 and &lt;70 years of age who have never received Zoster Vaccine, Live</description>
        </group>
        <group group_id="E4">
          <title>Group 4: First Dose Participants ≥50 and &lt;60 Years of Age</title>
          <description>Herpes zoster history-negative participants ≥50 and &lt;60 years of age who have never received Zoster Vaccine, Live</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (15.0)</default_vocab>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="201"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="199"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Haemorrhagic anaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="199"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="199"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="199"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="199"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="199"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>Pelvic abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="199"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>Peritonitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="199"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Pelvic fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="199"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>Wound haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Prostate cancer metastatic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="201"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dementia Alzheimer's type</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="201"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="201"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="201"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (15.0)</default_vocab>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="75" subjects_at_risk="201"/>
                <counts group_id="E2" subjects_affected="58" subjects_at_risk="199"/>
                <counts group_id="E3" subjects_affected="61" subjects_at_risk="100"/>
                <counts group_id="E4" subjects_affected="62" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Injection-site erythema</sub_title>
                <counts group_id="E1" events="43" subjects_affected="43" subjects_at_risk="201"/>
                <counts group_id="E2" events="47" subjects_affected="47" subjects_at_risk="199"/>
                <counts group_id="E3" events="41" subjects_affected="41" subjects_at_risk="100"/>
                <counts group_id="E4" events="40" subjects_affected="40" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>Injection-site pain</sub_title>
                <counts group_id="E1" events="47" subjects_affected="47" subjects_at_risk="201"/>
                <counts group_id="E2" events="29" subjects_affected="28" subjects_at_risk="199"/>
                <counts group_id="E3" events="46" subjects_affected="42" subjects_at_risk="100"/>
                <counts group_id="E4" events="48" subjects_affected="48" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>Injection-site pruritus</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="201"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="199"/>
                <counts group_id="E3" events="9" subjects_affected="9" subjects_at_risk="100"/>
                <counts group_id="E4" events="11" subjects_affected="11" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>Injection-site swelling</sub_title>
                <counts group_id="E1" events="30" subjects_affected="30" subjects_at_risk="201"/>
                <counts group_id="E2" events="24" subjects_affected="24" subjects_at_risk="199"/>
                <counts group_id="E3" events="29" subjects_affected="29" subjects_at_risk="100"/>
                <counts group_id="E4" events="33" subjects_affected="33" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="201"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="199"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="100"/>
                <counts group_id="E4" events="6" subjects_affected="6" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="11" subjects_affected="8" subjects_at_risk="201"/>
                <counts group_id="E2" events="8" subjects_affected="4" subjects_at_risk="199"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="100"/>
                <counts group_id="E4" events="13" subjects_affected="9" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the sponsor as confidential must be deleted prior to submission.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Vice President, Late Stage Development Group Leader</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp.</organization>
      <phone>1-800-672-6372</phone>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
